- Home
- IVVD vs CATO Comparison
IVVD vs CATO Comparison
Compare IVVD & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | CATO |
|---|---|---|
| Founded | 2020 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 68.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IVVD | CATO |
|---|---|---|
| Price | $2.39 | $3.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 12.4M | 38.3K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,039,000.00 | ★ $660,062,000.00 |
| Revenue This Year | $103.88 | N/A |
| Revenue Next Year | $171.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | N/A |
| 52 Week Low | $0.35 | $2.19 |
| 52 Week High | $3.07 | $4.92 |
Technical Indicators
Market Signals| Indicator | IVVD | CATO |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 39.45 |
| Support Level | $2.15 | $3.13 |
| Resistance Level | $2.59 | $3.57 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 60.40 | 30.00 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.